Survival-inferred fragility index of FDA-approved cancer drugs using surrogate endpoints

被引：0
|
作者：
Ofer, Jonathan
Gilboa, Shai
Pras, Yarden
Markel, Gal
Bomze, David
Meirson, Tomer
机构：
[1] Beilinson Med Ctr, Davidoff Canc Ctr, Rabin Med Ctr, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1573
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
    Gyawali, Bishal
    Hey, Spencer P.
    Kesselheim, Aaron S.
    ECLINICALMEDICINE, 2020, 21
  • [32] Assessment of robustness of randomized controlled trials for the treatment of cholangiocarcinoma in three domains: survival-inferred fragility index, restricted mean survival time, and the spin effect
    Horesh, Nir
    Bomze, David
    Lim, Chetana
    Markel, Gal
    Meirson, Tomer
    Azoulay, Daniel
    HEPATOBILIARY SURGERY AND NUTRITION, 2021,
  • [33] FDA-approved drugs as PIM-1 kinase inhibitors: A drug repurposed approach for cancer therapy
    Rathi, Aanchal
    Noor, Saba
    Sulaimani, Md Nayab
    Ahmed, Shahbaz
    Taiyab, Aaliya
    Alajmi, Mohamed F.
    Khan, Faez Iqbal
    Hassan, Md. Imtaiyaz
    Haque, Mohammad Mahfuzul
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2025, 292
  • [34] Consideration of Potential Drug-Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer
    Pilon, Dominic
    Ellis, Lorie A.
    Xiao, Yongling
    Behl, Ajay S.
    Lefebvre, Patrick
    AMERICAN JOURNAL OF THERAPEUTICS, 2019, 26 (03) : E422 - E424
  • [35] Computational Screening of FDA-Approved Hepatitis C Drugs for Inhibition of VEGFR2 in Liver Cancer
    Roney, Miah
    Issahaku, Abdul Rashid
    Tufail, Nasir
    Wilhelm, Anke
    Aluwi, Mohd Fadhlizil Fasihi Mohd
    CHEMISTRYSELECT, 2024, 9 (35):
  • [36] The increase in FDA-approved novel cancer drugs over the last 5 years: What factors are involved?
    Amanam, Idoroenyi Usua
    Gardner, Austin Blake
    Young-Lin, Nichole
    Chan, John K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer
    Yang, Liyan
    Wang, Zhonglei
    BIOMEDICINES, 2021, 9 (06)
  • [38] Pharmacokinetic drug-drug interactions: an insight into recent US FDA-approved drugs for prostate cancer
    Gajula, Siva Nageswara Rao
    Reddy, Gangireddy Navitha
    Reddy, Dannarm Srinivas
    Sonti, Rajesh
    BIOANALYSIS, 2020, 12 (22) : 1647 - 1664
  • [39] Modulation of biopharmaceutical properties of drugs using sulfonate counterions: A critical analysis of FDA-approved pharmaceutical salts
    Bharate, Sonali S.
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2021, 66
  • [40] FDA-approved Drugs Selected Using Virtual Screening Bind Specifically to G-quadruplex DNA
    Castillo-Gonzalez, Daimel
    Perez-Machado, Gisselle
    Guedin, Aurore
    Mergny, Jean-Louis
    Cabrera-Perez, Miguel-Angel
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (12) : 2164 - 2173
12345